Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 21Recruiting 20Active not recruiting 18Terminated 8Withdrawn 4Unknown 3Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Lymphoma 1Histiocytic Sarcoma 1Dendritic Cell Sarcoma, Interdigitating 1Dendritic Cell Sarcoma, Follicular 1

Interventions

Specimen Handling 3trastuzumab deruxtecan 1tivozanib 1pembrolizumab 1pegamotecan 1fludarabine phosphate 1envafolimab 1cemiplimab 1atezolizumab 1apatinib 1aldesleukin 1X-Rays 1Vincristine 1Vaccines 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Nanoparticles 1Magnetic Resonance Spectroscopy 1Health Care Economics and Organizations 1HMPL-013 1Everolimus 1Cyclophosphamide 1Biopsy 1Biomarkers 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × pembrolizumab × Sarcoma × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡